Figure 1.

Discovery and SARS-CoV-2 neutralization of 1F. (A) Occurrence frequency of sequenced clones. (B) ELISA binding assay of selected antibodies to RBD protein. Experiments were performed in triplicate. (C) Representative SPR sensorgrams of 1F with RBD. (D and E) Binding ELISA assays of mutated RBD proteins on 1F. Experiments were performed in triplicate. (F) Summary of EC₅₀ values in ELISA assays performed in (D) and (E). NC means EC₅₀ cannot be calculated due to poor binding ability. (G) ACE2 competition of 1F by ELISA assay. Experiments were performed in quadruplicate. (H) ACE2 competition of 1F by SPR. Representative sensorgram of two independent experiments is shown. (I) Neutralization of 1F against lentivirus-vectored SARS-CoV-2 pseudovirus. (J) Neutralization of 1F on authentic SARS-CoV-2 virus. (K) Inhibition of 1F on SARS-CoV-2 spike mediated cell-cell fusion. (L) Neutralization of 1F against lentivirus-vectored SARS-CoV pseudovirus. All the experiments were performed in triplicates.